This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
Wes Yin, PhD
Advertisement
Articles by Wes Yin, PhD
This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.
Advertisement
Latest Updated Articles
- The Value of Survival Gains in Myelodysplastic Syndromes
January 16th 2017
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis
5